Use of nilotinib in the diabetic patient
A 42-year-old man, diabetic patient, after CML Ph+ diagnosis started a treatment with imatinib reaching both CHR and CCyR within 6 months. Because of two episodes of vitreous haemorrhage the treatment was discontinued for four months with the lost of the CCyR and the maintenance of the CHR. The pati...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
SEEd
2015-10-01
|
| Rangatū: | Clinical Management Issues |
| Ngā marau: | |
| Urunga tuihono: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1094 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|